Related Experiment Video
Updated: Feb 22, 2026
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Selective inhibition of NF-kappaB and surfactant therapy in experimental meconium-induced lung injury
J Kopincova1, P Mikolka, M Kolomaznik
1Biomedical Center Martin and Department of Physiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia. daniela.mokra@jfmed.uniba.sk.
Abstract:
Meconium aspiration syndrome (MAS) in newborns is characterized mainly by respiratory failure due to surfactant dysfunction and inflammation. Previous meta-analyses did not prove any effect of exogenous surfactant treatment nor glucocorticoid administration on final outcome of children with MAS despite oxygenation improvement. As we supposed there is the need to intervene in both these fields simultaneously, we evaluated therapeutic effect of combination of exogenous surfactant and selective inhibitor of NF-kappaB (IKK-NBD peptide). Young New Zealand rabbits were instilled by meconium suspension and treated by surfactant alone or surfactant in combination with IKK-NBD, and oxygen-ventilated for 5 h. PaO(2)/FiO(2), oxygenation index, oxygen saturation and ventilation efficiency index were evaluated every hour; post mortem, total and differential leukocyte counts were investigated in bronchoalveolar lavage fluid (BALF) and inflammatory, oxidative and apoptotic markers were assessed in lung tissue homogenates. Exogenous surfactant combined with IKK-NBD improved oxygenation, reduced neutrophil count in BALF and levels of IL-1beta, IL-6, p38 MAPK and caspase 3 in comparison with surfactant-only therapy. It seems that inhibition of inflammation may be strong supporting factor in surfactant treatment of MAS.
Insights
Combining surfactant with an inflammation inhibitor improves respiratory outcomes in newborns with meconium aspiration syndrome (MAS). This novel approach targets both surfactant dysfunction and inflammation, offering a potential new treatment strategy for MAS.
Area of Science:
- Neonatal Medicine
- Respiratory Physiology
- Pharmacology
Background:
- Meconium aspiration syndrome (MAS) causes respiratory failure in newborns due to surfactant dysfunction and inflammation.
- Previous treatments like surfactant or glucocorticoids alone have not improved overall outcomes.
- Simultaneous intervention in both surfactant function and inflammation is hypothesized to be more effective.
Purpose of the Study:
- To evaluate the therapeutic effect of combining exogenous surfactant with a selective NF-kappaB inhibitor (IKK-NBD peptide) in a rabbit model of MAS.
- To assess the impact of this combination therapy on respiratory parameters and inflammatory markers.
Main Methods:
- New Zealand rabbits were instilled with meconium and treated with surfactant alone or surfactant plus IKK-NBD.
- Animals were mechanically ventilated for 5 hours, with respiratory parameters monitored hourly.
- Post-mortem analyses included bronchoalveolar lavage fluid cell counts and lung tissue inflammatory marker assessment.
Main Results:
- The combination of surfactant and IKK-NBD significantly improved oxygenation compared to surfactant alone.
- This combined therapy reduced neutrophil counts in bronchoalveolar lavage fluid.
- Levels of inflammatory markers (IL-1beta, IL-6), oxidative stress markers, and apoptosis markers (caspase 3) were decreased in lung tissue.
Conclusions:
- Simultaneous administration of exogenous surfactant and an NF-kappaB inhibitor (IKK-NBD) enhances oxygenation in MAS.
- Inhibition of inflammation appears to be a crucial supportive factor for surfactant therapy in MAS.
- This combination therapy presents a promising strategy for managing MAS by addressing both key pathological mechanisms.
